product name Bufexamac
Description: Bufexamac is a potent COX inhibitor for IFN-α release with EC50 of 8.9 μM. Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Treatment of peripheral blood mononuclear cells with bufexamac inhibits the secretion of IFN-α. Bufexamac is a frequent and relevant contact sensitizer. Bufexamac is a non-steroidal anti-inflammatory drug.
References: Nat Biotechnol. 2011 Mar;29(3):255-65.
223.27
Formula
C12H17NO3
CAS No.
2438-72-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 45 mg/mL (201.5 mM)
Water: <1 mg/mL
Ethanol: 3 mg/mL (13.4 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19408093
| In Vitro |
In vitro activity: Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Treatment of peripheral blood mononuclear cells with bufexamac inhibits the secretion of IFN-α. Bufexamac is a frequent and relevant contact sensitizer. Bufexamac is a non-steroidal anti-inflammatory drug. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Nat Biotechnol. 2011 Mar;29(3):255-65. |
